Home » Regulatory » Bulletins

AATB bulletins are related to standards changes and regulatory changes. The bulletins on this page cover regulatory issues. Bulletins related to changes in AATB's Standards are referenced under the Standards section. 

Bulletin 17-10

Published on: October 10, 2017

As part of a notice recently issued by the FDA, the regulator clarified that the Travel Notice Posting Dates table, maintained by the CDC and used by tissue banks to identify areas with active transmission risk of Zika virus (ZIKV) in other countries as part of the donor risk assessment process, HAS NOW BEEN ARCHIVED for historical purposes.

Read More »

Bulletin 17-9

Published on: September 18, 2017

In response to an inquiry from an accredited member organization, the U.S. Food and Drug Administration (FDA) provided the American Association of Tissue Banks (AATB) with a clarification of the requirements of Sec. 1271.210 about documentation on supplies and reagents applicable to recovery establishments working in partnership with processors.

Read More »

Bulletin 17-8

Published on: September 07, 2017

The U.S. Food and Drug Administration (FDA) released a finalized guidance on Wednesday to help manufacturers of non-reproductive human cells, tissues and cellular and tissue-based products (HCT/Ps) understand the agency's recommendations for complying with the requirements to investigate and report HCT/P deviations.

Read More »

Bulletin 17-6

Published on: May 25, 2017

The US Food and Drug Administration (FDA) released details on the structure of its newly realigned Office of Regulatory Affairs (ORA). The move is part of FDA's program alignment, which transitions from geographic management to FDA-regulated product type based management. "Specializing by FDA-regulated product type more closely mirrors the organizational model of FDA's centers and the industries we regulate," FDA writes.​

Read More »

Bulletin 17-3

Published on: March 13, 2017

We would like to bring to your attention important information for human cell, tissue and cellular and tissue-based product establishments regarding Zika virus. This information is posted on the FDA's web site.

Read More »

Bulletin 17-2

Published on: January 13, 2017

Yesterday (January 12, 2017), Organ Recovery Systems, Inc. (ORS) posted a news update to their webpage regarding reports of Contaminated Organ Preservation Fluid - SPS-1®. ORS is in the process of conducting a comprehensive investigation of available information and indicated all of their customers have been notified via email.

Read More »

Bulletin 17-1

Published on: January 04, 2017

The Food and Drug Administration (FDA) is announcing a public workshop entitled "Identification and Characterization of the Infectious Disease Risks of Human Cells, Tissues, and Cellular and Tissue-based Products."

Read More »

Bulletin 16-15

Published on: September 13, 2016

Yesterday, the Food and Drug Administration (FDA) released a final guidance document that describes recommendations to use a Nucleic Acid Test (NAT) for West Nile Virus (WNV) for testing, with few exceptions, living donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps).

Read More »

Bulletin 16-14

Published on: August 17, 2016

Today, the Food and Drug Administration (FDA) published a notice of availability of a Final Guidance Document that recommends use of an FDA-licensed nucleic acid test (NAT) for hepatitis B virus (HBV) deoxyribonucleic acid (DNA) when testing donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps).

Read More »

Bulletin 16-13

Published on: July 29, 2016

We have been communicating with officials at Florida's Agency for Health Care Administration (AHCA). It is time to submit a request for extension to the temporary waiver granted to AATB-accredited tissue banks in October 2014 (see AATB Bulletin #14-08, "Final Order Granted: Extension to Temporary Waiver").

Read More »